|
MedImmune Logo
MedImmune, LLC was a wholly owned subsidiary of AstraZeneca before February 14, 2019, when it was announced that the MedImmune name and branding would be discontinued in favor of AstraZeneca. MedImmune was founded in 1988 as Molecular Vaccines, Inc, and was purchased in 2007 for $15.6 billion. Its main offices were located in Gaithersburg, MD, Cambridge, UK, and Mountain View, CA. It produced '' Synagis'', a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and ''FluMist'', a nasal spray influenza vaccine introduced in 2004. MedImmune acquired ''FluMist'' when it purchased Aviron in 2002 for US$ 1.5 billion. ''FluMist'' sales totaled US$ 104 million in 2008, US$ 54.8 million in 2007, and US$ 36.4 million in 2006. ''FluMist'' was approved for children two years of age and older in 2007, but initially was approved only for healthy people ages 5 to 49, a significant limitation because it el ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
MedImmune Logo
MedImmune, LLC was a wholly owned subsidiary of AstraZeneca before February 14, 2019, when it was announced that the MedImmune name and branding would be discontinued in favor of AstraZeneca. MedImmune was founded in 1988 as Molecular Vaccines, Inc, and was purchased in 2007 for $15.6 billion. Its main offices were located in Gaithersburg, MD, Cambridge, UK, and Mountain View, CA. It produced '' Synagis'', a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and ''FluMist'', a nasal spray influenza vaccine introduced in 2004. MedImmune acquired ''FluMist'' when it purchased Aviron in 2002 for US$ 1.5 billion. ''FluMist'' sales totaled US$ 104 million in 2008, US$ 54.8 million in 2007, and US$ 36.4 million in 2006. ''FluMist'' was approved for children two years of age and older in 2007, but initially was approved only for healthy people ages 5 to 49, a significant limitation because it el ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Cambridge Antibody Technology
Cambridge Antibody Technology (officially Cambridge Antibody Technology Group Plc, informally CAT) was a biotechnology company headquartered in Cambridge, England, United Kingdom. Its core focus was on antibody therapeutics, primarily using Phage Display and Ribosome Display technology. Phage Display Technology was used by CAT to create adalimumab, the first fully human antibody blockbuster drug. Humira, the brand name of adalimumab, is an anti-TNF antibody discovered by CAT as D2E7, then developed in the clinic and marketed by Abbvie, formerly Abbott Laboratories. CAT was also behind belimumab, the anti-BlyS antibody drug marketed as Benlysta and the first new approved drug for systemic lupus in more than 50 years. In 2018, the Nobel Prize organisation awarded one quarter of the Nobel Prize in Chemistry to a founding member of CAT, Sir Greg Winter FRS "for the phage display of peptides and antibodies.". Founded in 1989, CAT was acquired by AstraZeneca for £702m in 2006. A ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Nirsevimab
Nirsevimab, sold under the brand name Beyfortus, is a human recombinant monoclonal antibody with activity against respiratory syncytial virus, or RSV for infants. It is under development by AstraZeneca and Sanofi. Nirsevimab is designed to bind to the fusion protein on the surface of the RSV virus. The most common side effects reported for nirsevimab are rash, pyrexia (fever) and injection site reactions (such as redness, swelling and pain where the injection is given). Nirsevimab was approved for medical use in the European Union in November 2022. Adverse effects No major hypersensitivity reactions have been reported, and adverse events of grade 3 or higher were only reported in 8% (77 of 968) of participants in clinical trial NCT02878330. Pharmacology Mechanism of action Nirsevimab binds to the prefusion conformation of the RSV fusion protein, i.e. it binds to the site at which the virus would attach to a cell; effectively rendering it useless. It has a modified Fc re ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Anifrolumab
Anifrolumab, sold under the brand name Saphnelo, is a monoclonal antibody used for the treatment of systemic lupus erythematosus (SLE). It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-α and interferon-β. Anifrolumab was approved for medical use in the United States in July 2021, and in the European Union in February 2022. The U.S. Food and Drug Administration considers it to be a first-in-class medication. Mechanism of Action In systemic lupus erythematosus, the body can produce a great amount of type 1 interferon, which activates the immune system excessively and creates problems for lupus patients. Anifrolumab acts to block INF-1 from sending signals to other immune cells, which prevents the body from being attacked by itself. Adverse effects The most common adverse effect was shingles, which occurred in 5% of patients in the low-dose group, to 10% in the high-dose group, and to 2% in the placebo group. Overall ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Tralokinumab
Tralokinumab sold under the brand names Adtralza (EU/UK) and Adbry (US) among others, is a human monoclonal antibody used for the treatment of atopic dermatitis. Tralokinumab targets the cytokine interleukin 13. The most common side effects include upper respiratory tract infections (colds and other infections of the nose and throat), reactions at the injection site, and redness and discomfort in the eye. Tralokinumab was approved for medical use in the European Union and in the United Kingdom in June 2021. It was approved for medical use in the United States in December 2021. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. Medical uses Tralokinumab is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy. In the United States, tralokinumab is indicated for the treatment of moderate-to-severe atopic dermatitis in adults whose disease is not adequately controlled with t ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Benralizumab
Benralizumab, sold under the brand name Fasenra, is a monoclonal antibody medication which is developed by MedImmune for the treatment of asthma. It is directed against the alpha-chain of the interleukin-5 receptor ( CD125). Two phase III clinical trials of benralizumab reported meeting their primary endpoints in 2016. It was approved by the US Food and Drug Administration in November 2017 for the treatment of severe eosinophilic asthma. It was granted designation as an orphan drug An orphan drug is a pharmaceutical agent developed to treat medical conditions which, because they are so rare, would not be profitable to produce without government assistance. The conditions are referred to as orphan diseases. The assignment of ... by the Food and Drug Administration for treatment of eosinophilic oesophagitis in August 2019. References External links * Antiasthmatic drugs Monoclonal antibodies AstraZeneca brands Orphan drugs {{respiratory-system-drug-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Moxetumomab Pasudotox
Moxetumomab pasudotox, sold under the brand name Lumoxiti, is an anti- CD22 immunotoxin medication for the treatment of adults with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog. Moxetumomab pasudotox is a CD22-directed cytotoxin and is the first of this type of treatment for adults with HCL. The drug consists of the binding fragment (Fv) of an anti-CD22 antibody fused to a toxin called PE38. This toxin is a 38 kDa fragment of Pseudomonas exotoxin A. Hairy cell leukemia (HCL) is a rare, slow-growing cancer of the blood in which the bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. HCL is named after these extra B cells which look “hairy” when viewed under a microscope. As the number of leukemia cells increases, fewer healthy white blood cells, red blood cells and platelets are produced. Medical uses Moxetumomab pas ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Tremelimumab
Tremelimumab, sold under the brand name Imjudo, is a fully human monoclonal antibody against CTLA-4. It is an immune checkpoint blocker. Tremelimumab was approved for unresectable hepatocellular carcinoma medical use in the United States in October 2022. Medical uses Tremelimumab is indicated, in combination with durvalumab, for the treatment of adults with unresectable hepatocellular carcinoma. Mechanism of action Tremelimumab aims to stimulate an immune system attack on tumors. Cytotoxic T lymphocytes (CTLs) can recognize and destroy cancer cells. However, there is also an inhibitory mechanism (immune checkpoint) that interrupts this destruction. Tremelimumab turns off this inhibitory mechanism and allows CTLs to continue to destroy the cancer cells. Tremelimumab binds to the protein CTLA-4, which is expressed on the surface of activated T lymphocytes and inhibits the killing of cancer cells. Tremelimumab blocks the binding of the antigen-presenting cell ligands B7.1 ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Durvalumab
Durvalumab (trade name Imfinzi) is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279). Durvalumab is known as an immune checkpoint inhibitor drug. Medical uses The US Food and Drug Administration (FDA) has approved durvalumab for certain types of bladder, lung, and biliary tract cancer: * Adults with locally advanced or metastatic urothelial carcinoma who either have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. * Adults with unresectable, Stage III non-small cell lung cancer whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. * In combination with etoposide and either carboplatin or cisplatin ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Department Of Health And Human Services
The United States Department of Health and Human Services (HHS) is a cabinet-level executive branch department of the U.S. federal government created to protect the health of all Americans and providing essential human services. Its motto is "Improving the health, safety, and well-being of America". Before the separate federal Department of Education was created in 1979, it was called the Department of Health, Education, and Welfare (HEW). HHS is administered by the Secretary of Health and Human Services, who is appointed by the president with the advice and consent of the United States Senate. The position is currently held by Xavier Becerra. The United States Public Health Service Commissioned Corps, the uniformed service of the PHS, is led by the Surgeon General who is responsible for addressing matters concerning public health as authorized by the secretary or by the assistant secretary for Health in addition to his or her primary mission of administering the Commissione ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
2009 Flu Pandemic
The 2009 swine flu pandemic, caused by the H1N1 influenza virus and declared by the World Health Organization (WHO) from June 2009 to August 2010, is the third recent flu pandemic involving the H1N1 virus (the first being the 1918–1920 Spanish flu pandemic and the second being the 1977 Russian flu). The first two cases were discovered independently in the United States in April 2009. The virus appeared to be a new strain of H1N1 that resulted from a previous triple reassortment of bird, swine, and human flu viruses which further combined with a Eurasian pig flu virus, leading to the term "swine flu". Some studies estimated that the real number of cases including asymptomatic and mild cases could be 700 million to 1.4 billion people—or 11 to 21 percent of the global population of 6.8 billion at the time. The lower value of 700 million is more than the 500 million people estimated to have been infected by the Spanish flu pandemic. However, the Spanish flu infected approximat ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
